Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies.

British journal of haematology·2026
Same author

Small Extracellular Vesicle-Associated microRNA in Cancer: Biology and Applications in Translational Research and Precision Oncology.

Cancers·2026
Same author

Breaking the Balance: Baseline Oxidative Stress and DNA Repair Capacity in Multiple Myeloma Therapy.

Cancers·2026
Same author

Efficacy and Safety of PD-1 Inhibitor-Based Regimens in Patients with Melanoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal of clinical medicine·2026
Same author

Prognostic value of <i>MYD88</i>/<i>CXCR4</i> mutation allele fraction in Waldenström macroglobulinemia using a multiplex ddPCR assay.

HemaSphere·2026
Same author

Safety profile of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta-analysis of proportions from clinical trials.

British journal of haematology·2026

Related Experiment Video

Updated: Oct 18, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K

BCMA in Multiple Myeloma-A Promising Key to Therapy.

Martina Kleber1,2, Ioannis Ntanasis-Stathopoulos3, Evangelos Terpos3

  • 1Division of Internal Medicine, University Hospital of Zurich, 8091 Zurich, Switzerland.

Journal of Clinical Medicine
|September 28, 2021
PubMed
Summary

New B-cell maturation antigen (BCMA) targeted therapies, including antibody-drug conjugates, bispecific T cell engagers, and CAR T cells, offer hope for treating relapsed or refractory multiple myeloma (MM). These advanced treatments show promise in improving outcomes for heavily pretreated patients.

Keywords:
ADCBCMABiTECAR T cellantibodyconjugatedimmunotherapymultiple myeloma

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.8K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K

Related Experiment Videos

Last Updated: Oct 18, 2025

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.8K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Multiple myeloma (MM) remains incurable despite advances in proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.
  • B-cell maturation antigen (BCMA) is highly expressed on malignant plasma cells, making it a promising therapeutic target.
  • Refractory or relapsed MM after standard therapy presents a significant unmet clinical need.

Purpose of the Study:

  • To review emerging BCMA-targeted treatment modalities for multiple myeloma.
  • To update on the efficacy and safety of antibody-drug conjugates (ADCs), bispecific T cell engagers (BITEs), and chimeric antigen receptor (CAR) T cell therapy.
  • To assess the potential of BCMA-targeted therapies to change the treatment paradigm for MM.

Main Methods:

  • Comprehensive review of preclinical and clinical trial data.
  • Analysis of current results from representative BCMA-targeted therapy trials.
  • Evaluation of efficacy and safety profiles of various BCMA-targeted agents.

Main Results:

  • BCMA-targeted therapies represent a new era in MM treatment for relapsed/refractory patients.
  • Antibody-drug conjugates (ADCs), bispecific T cell engagers (BITEs), and CAR T cell therapies are evolving treatment concepts.
  • Clinical trial results suggest these modalities can address unmet needs and improve outcomes in heavily pretreated MM.

Conclusions:

  • BCMA-targeted treatments hold significant promise for improving outcomes in multiple myeloma.
  • These novel therapies have the potential to alter the treatment landscape for both newly diagnosed and refractory MM.
  • Further research and clinical trials are essential to fully realize the benefits of BCMA-targeted approaches.